Verapamil: Nursing Drug Guide, Heart Block & Hold Rules
Count apical pulse and review the rhythm strip before every dose—verapamil slows AV conduction and can stack with beta-blockers or digoxin into bradycardia, high-degree block, or hypotension. Strong negative inotropy worsens heart failure in vulnerable patients; constipation is the most common oral adverse effect nurses must proactively teach.
Verapamil prolongs AV nodal conduction and reduces myocardial contractility. It can cause bradycardia, second- or third-degree heart block, and symptomatic hypotension—risk rises when beta-blockers, digoxin, or other nodal drugs share the MAR. Count apical pulse for a full minute before every oral dose and review telemetry or a recent electrocardiogram (ECG) before IV use. IV verapamil is contraindicated for atrial fibrillation or flutter rate control when Wolff-Parkinson-White accessory pathway is present (oral rate control is also contraindicated in that setting). Additional restrictions apply only to IV use—such as co-administration with IV beta-blockers within hours and wide-complex ventricular tachycardia—so do not apply the full IV contraindication list to every outpatient oral order without prescriber context.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every dose, count apical pulse for a full minute and confirm no high-degree AV block—especially when beta-blockers or digoxin share the MAR. Hold verapamil for symptomatic bradycardia, block, or systolic BP below 90 mmHg; never use IV verapamil for AF/flutter rate control when Wolff-Parkinson-White accessory pathway is present. Teach constipation prevention from day one.
Most common brand names
Verapamil is widely known as Calan and Isoptin (immediate-release tablets) and in extended-release forms such as Calan SR, Isoptin SR, Verelan, and Covera-HS. IV products are labeled verapamil hydrochloride injection (2.5 mg/mL). Always verify formulation on the MAR during medication reconciliation—IR, ER, and IV are not interchangeable.
Do not confuse verapamil with diltiazem or dihydropyridine agents such as amlodipine; verapamil and diltiazem slow heart rate and AV conduction, unlike amlodipine.
Why we give it — Indications
Per verapamil hydrochloride tablet and injection labeling, verapamil is used for hypertension, chronic stable and vasospastic angina, ventricular rate control in chronic atrial flutter or fibrillation (with digitalis when appropriate), PSVT prophylaxis, and rapid IV conversion of PSVT or temporary AF/flutter rate control when oral therapy is not feasible.
| Use | Detail |
|---|---|
| Essential hypertension (oral) | Lowers blood pressure by decreasing systemic vascular resistance; monitor for hypertension symptoms and bradycardia after initiation |
| Angina (oral) | Reduces coronary spasm and myocardial oxygen demand; watch for worsening chest pain after start or dose increase |
| Oral rate control (AF/flutter) | With digitalis in chronic AF/flutter—requires pulse and ECG monitoring; contraindicated with accessory bypass tract |
| IV PSVT conversion / AF rate control | Bolus 5–10 mg over ≥2 minutes with continuous ECG and BP monitoring; contraindicated for AF/flutter when WPW present; PSVT with accessory pathway may be treated IV per labeling when clinically appropriate |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Verapamil blocks L-type calcium channels in vascular smooth muscle and cardiac tissue, causing arterial vasodilation, slowing AV nodal conduction, and reducing myocardial contractility. Unlike dihydropyridines, verapamil can reduce heart rate and prolong the PR interval—patients may notice rhythm changes or an irregular heartbeat sensation when rate slows. Negative inotropic effects may worsen heart failure in patients with severe left ventricular dysfunction per labeling.
IV verapamil slows ventricular response in atrial fibrillation by blocking AV node conduction; conversion to sinus rhythm is uncommon. In Wolff-Parkinson-White syndrome with AF/flutter, AV nodal block can force conduction through the accessory pathway and dangerously increase ventricular rate.
Dosing overview
Dosing depends on formulation (IR tablet, ER capsule/tablet, IV). Titrate slowly in elderly patients, hepatic impairment, and when adding nodal drugs. Daily oral doses above 480 mg have not been established as safe in labeling.
Renal and hepatic adjustment
| Population | Guidance | Nursing note |
|---|---|---|
| Hepatic impairment | Use ~30% of normal oral dose; half-life may prolong to 14–16 h | Monitor PR interval and clinical response; contact pharmacy before titration |
| Renal impairment | Not removed by hemodialysis; use cautiously | Repeated IV doses may accumulate in severe renal/hepatic failure per injection labeling |
| ER bedtime products | 100–400 mg once daily at bedtime per ER (PM) labeling | Swallow whole or sprinkle on applesauce per specific ER instructions—do not crush unless pharmacy confirms |
On a small screen, swipe or scroll sideways to see the full table.
Missed dose (oral): Take when remembered unless near the next dose—do not double. After a missed day, reassess pulse and blood pressure before restarting if the patient felt dizzy or had low readings at home.
Before you give it — Safety check
Pretreatment checks
- Count apical pulse for a full minute and obtain blood pressure using proper blood pressure measurement technique
- Review rhythm strip or ECG for PR prolongation, second- or third-degree block, or pre-excitation before IV use
- Reconcile nodal drugs: digoxin, metoprolol and other beta-blockers, ivabradine, clonidine
- Confirm formulation (IR vs ER vs IV), allergy status, grapefruit intake, and hold parameters on the MAR
Contraindications (labeling)
Several contraindications apply to both oral and IV verapamil (for example accessory-pathway AF/flutter, high-degree AV block without pacemaker, cardiogenic shock). Others are IV-specific (ventricular tachycardia with wide QRS, IV beta-blocker overlap within hours). Outpatient oral therapy still requires pulse, blood pressure, and conduction checks—but do not assume every IV contraindication list item applies identically to every oral order without prescriber context.
- Severe left ventricular dysfunction (oral); severe CHF unless PSVT-related (IV)
- Hypotension (systolic BP <90 mmHg) or cardiogenic shock
- Sick sinus syndrome without functioning ventricular pacemaker
- Second- or third-degree AV block without functioning ventricular pacemaker
- Atrial flutter or fibrillation with accessory bypass tract (WPW, LGL syndromes)—oral and IV rate control
- IV only: ventricular tachycardia (wide QRS); IV beta-blocker within a few hours
- Known verapamil hypersensitivity
Important warnings
- Cardiac conduction: Bradycardia, AV block, and asystole—additive with beta-blockers or digitalis
- Hypotension: Symptomatic hypotension ~1.5% with IV; oral hypotension 2.5% in trials
- Heart failure: Negative inotropy—acute worsening possible when EF <30% or wedge pressure >20 mmHg
- Hepatic injury: Transaminase elevations—periodic liver function monitoring prudent per labeling
- Constipation / ileus: Constipation 7.3% oral; reversible paralytic ileus reported infrequently
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Beta-blockers | Additive bradycardia, AV block, and contractility depression; IV combination contraindicated within hours | Verify oral overlap; hold either agent when HR or block criteria met; never co-administer IV forms close together |
| Digoxin | Serum digoxin may rise 50–75% in first week; additive nodal suppression | Monitor heart rate, PR interval, and digoxin toxicity signs; trend digoxin level per prescriber |
| Simvastatin | Verapamil inhibits CYP3A4—~2.5-fold simvastatin exposure in labeling study | Limit simvastatin to 10 mg daily when combined; contact pharmacist if exceeded |
| Grapefruit juice | May increase verapamil plasma levels | Include in intake history and patient teaching |
| Ivabradine | Increased exposure; may worsen bradycardia and conduction disturbances | Avoid combination per labeling; escalate if both appear on MAR without prescriber rationale |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Oral: IR tablets with food or without per prescriber; ER capsules/tablets must be swallowed whole unless specific ER labeling allows sprinkling on applesauce—never crush ER beads without pharmacy confirmation.
- Take oral doses at consistent times; ER bedtime products at bedtime per labeling
- Assist patients at fall risk when orthostatic dizziness appears after dosing
- For IV: continuous ECG and blood pressure monitoring required; defibrillator and emergency equipment readily available per injection labeling
- IV bolus over at least 2 minutes (3 minutes in older adults); program subsequent care via IV infusion pump setup when infusion ordered
- Inspect IV solution; avoid incompatible admixtures (precipitates above pH 6.0) per injection labeling
Initial IV use should occur where resuscitation and DC cardioversion are available. Confirm the rhythm is not ventricular tachycardia (wide QRS) before giving IV verapamil. Exclude accessory pathway-mediated AF before rate-control bolus—IV verapamil is indicated for PSVT including some WPW-associated tachycardias but contraindicated for AF/flutter with bypass tract.
Expected therapeutic response
- Gradual blood pressure reduction on oral therapy without symptomatic bradycardia or hypotension
- Decreased angina episodes or improved exercise tolerance when prescribed for coronary disease
- IV bolus: measurable heart rate reduction within 3–5 minutes for AF/flutter; ~60% PSVT conversion within 10 minutes in U.S. controlled trials per injection labeling
- Patient remains alert with adequate perfusion—excessive slowing or hypotension is not an acceptable response
- Oral bowel regimen maintains comfort—constipation should not be dismissed as minor
Red flags — Stop and act
Conduction collapse and perfusion failure can develop quickly when nodal drugs stack. Escalate immediately when hemodynamic or high-grade block cues appear.
- Heart rate below prescriber threshold or symptomatic bradycardia—hold verapamil and notify prescriber
- New or worsening second- or third-degree AV block on monitor or ECG
- Syncope, near-fainting, or systolic BP below 90 mmHg after oral or IV dose
- After IV bolus in AF: sudden wide-complex tachycardia with hypotension—suspect WPW pathway acceleration; stop and escalate emergently
- Worsening dyspnea, pulmonary congestion, or rapid weight gain suggesting heart failure decompensation
- Severe abdominal distension with absent bowel sounds—suspect paralytic ileus per labeling
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Constipation | 7.3% in oral trials (>1% drug-related) | Proactive bowel teaching; escalate if severe; report paralytic ileus signs |
| Bradycardia / AV block | Bradycardia 1.4% oral; AV block 1.2%; IV bradycardia 1.2% | Hold dose, obtain 12-lead ECG, notify prescriber; prepare pacing pathway if high-grade block |
| Hypotension | Oral 2.5%; IV symptomatic ~1.5% | Hold or reduce dose; orthostatic assessment; vasopressors per prescriber |
| Dizziness, headache, edema | Dizziness 3.3%; headache 2.2%; edema 1.9% | Correlate with vitals; teach slow position changes |
| CHF / pulmonary edema | 1.8% in oral trials | Monitor weights, lung sounds, perfusion; hold and notify if decompensation |
| Hepatic enzyme elevation | Usually transient; rare hepatocellular injury | Report jaundice or persistent GI symptoms; trend liver function tests per prescriber |
On a small screen, swipe or scroll sideways to see the full table.
Overdose and toxicity
Verapamil overdose may cause bradycardia, hypotension, heart block, and heart failure. There is no specific antidote. Observe at least 48 hours after oral overdose (especially sustained-release). Hemodialysis is not beneficial per labeling.
Supportive management (labeling)
- Bradycardia / AV block / asystole: Atropine, isoproterenol, calcium chloride, norepinephrine, cardiac pacing
- Hypotension: IV fluids, dopamine, norepinephrine, metaraminol, calcium gluconate/chloride
- WPW rapid ventricular response: DC-cardioversion, procainamide, or lidocaine per prescriber
- Beta-adrenergic stimulation and/or IV calcium may increase calcium flux and have been used in deliberate oral overdose
- High-dose continuous calcium infusion has been reported in refractory CCB overdose—per toxicology specialist guidance
- Contact local poison control or medical toxicology services per facility protocol
Supportive perfusion monitoring continues for hours—blood levels are not reliably useful in overdose assessment per labeling.
Look-alike / sound-alike and error prevention
- Verapamil vs vasopressin / vancomycin—verify generic name; all may appear as “V” orders on busy units
- Calan vs Cardizem (diltiazem)—both non-dihydropyridine CCBs with nodal effects but different dosing
- IR vs ER vs IV—dosing errors occur when ER is given QID or IV mg is confused with oral daily total
- Verapamil vs amlodipine—non-dihydropyridine vs dihydropyridine; verapamil slows HR, amlodipine often increases reflex HR
- Strength confusion—40, 80, 120 mg IR and 120–240 mg ER require independent double-check
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Pulse check | Apical pulse full minute before every oral dose; document rhythm regularity. |
| Constipation | Start bowel teaching at first dose—do not wait for impaction. |
| Grapefruit | Ask about juice and supplements at admission and discharge. |
| Beta-blocker overlap | Screen MAR each shift—oral overlap needs HR trending; IV overlap contraindicated within hours. |
| Commonly missed | Home verapamil ER continued with new inpatient nodal drugs; simvastatin above 10 mg with verapamil. |
| Ask pharmacy when | Simvastatin dose above limits, new CYP3A4 inhibitor, hepatic dose adjustment, or IV compatibility questions. |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Sick sinus syndrome | Contraindicated without pacemaker—risk of asystole or severe bradycardia. |
| Existing AV block | Contraindicated without pacemaker; monitor PR interval when first-degree block present. |
| Heart failure / low EF | Severe LV dysfunction contraindicated oral; use caution—worsening CHF reported. |
| Hepatic / renal impairment | Extensively hepatically metabolized; reduce oral dose ~70%; monitor labs via basic metabolic panel and LFTs. |
| Older adults | Start low; prolong IV push to ≥3 minutes; higher fall risk with bradycardia and hypotension. |
| Pregnancy | Older labeling used Pregnancy Category C language; current counseling should follow the product label and prescriber risk–benefit assessment. Animal data show embryo/fetal effects at high doses per labeling. |
| Lactation | Excreted in human milk; labeling recommends discontinuing nursing while verapamil is administered. LactMed notes low infant exposure at maternal doses up to 360 mg/day—coordinate with prescriber and pharmacist for individual risk-benefit. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Apical heart rate and rhythm before each oral dose; continuous telemetry during IV therapy
- Blood pressure supine and standing when symptomatic hypotension is possible
- PR interval and evidence of AV block on ECG after initiation or dose increase
- Bowel pattern, abdominal distension, and hydration when constipation risk is high
- Signs of heart failure, hepatic injury, or statin myopathy when interacting drugs are present
Document
- Formulation, dose, time, pre-dose heart rate, and rhythm interpretation
- Hold events with prescriber notification and response
- WPW exclusion documentation before IV AF rate-control bolus when protocol requires
- Simvastatin dose verification, grapefruit teaching, and bowel regimen education
Patient teaching
- Take doses at the same time each day; swallow ER products whole unless prescriber/pharmacy instructs otherwise
- Learn to count pulse and report slow heart rate, dizziness, fainting, or new irregular heartbeat sensations
- Rise slowly from sitting or lying—report lightheadedness before it leads to a fall
- Prevent constipation with fluids, fiber, and activity; ask about bowel regimen if no stool in 3 days
- Avoid grapefruit juice unless prescriber approves; tell all clinicians about verapamil before new medicines
- Contact local poison control or toxicology services per facility guidance if too many tablets were taken
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Symptomatic bradycardia or heart rate below institutional/prescriber threshold
- Second- or third-degree AV block without functioning pacemaker
- Systolic blood pressure below 90 mmHg or symptomatic hypotension/syncope
- Known verapamil hypersensitivity or severe left ventricular dysfunction per contraindication
- IV order for AF/flutter rate control when accessory bypass tract (WPW) is present or suspected
- Planned IV verapamil within a few hours of IV beta-blocker
- Simvastatin above 10 mg daily with verapamil until pharmacy clarifies
- Suspected overdose with bradycardia, block, or marked hypotension
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Verapamil is often filed with “blood pressure meds,” but its nodal and inotropic effects make it closer to a rate-control drug than amlodipine. The worst failures happen when nurses give the next dose despite a falling heart rate because blood pressure still looks acceptable—or when IV rate control is ordered without excluding WPW in atrial fibrillation.
1. Check-before-you-give protocol
- Right patient, drug, dose, route, time—and right rhythm context
- Apical pulse full minute plus blood pressure before every oral dose
- Review MAR for beta-blocker, digoxin, ivabradine, and duplicate CCB orders
- For IV: confirm rhythm diagnosis, WPW exclusion for AF rate control, and slow-push timing
2. High-alert and safety badge
Not a universal high-alert drug, but IV conversion and nodal suppression require ECG-level vigilanceTreat first inpatient doses and IV boluses with the same conduction monitoring used for digoxin and beta-blocker titration: pulse, rhythm, and prescriber hold parameters before administration.
3. Clinical workflow: hold and question rules
- If PR interval lengthens or heart rate falls after titration, hold the next dose and obtain 12-lead ECG before restarting
- If IV bolus produces hypotension lasting more than a few minutes, hold further doses and notify prescriber per protocol
- For suspected overdose, initiate supportive monitoring pathway—calcium, pacing, vasopressors per prescriber; contact poison control per protocol
4. Critical teach-back questions
- “How will you check whether this medicine is slowing your heart too much?” (Patient should mention counting pulse and reporting dizziness, fainting, or unusual fatigue.)
- “What should you do about grapefruit juice and constipation while taking verapamil?” (Patient should avoid grapefruit unless prescriber approves and use fluids/fiber or ask about bowel regimen early.)
5. Care coordination
Pharmacist: Consult for simvastatin dose limits, CYP3A4 interactions, IV compatibility, and formulation changes (IR vs ER)
Prescriber: Notify for symptomatic bradycardia, AV block, hypotension, ileus, or WPW concern before IV AF rate control
🧠 Quick mental checklist
- What is the apical heart rate and rhythm before this dose?
- Are beta-blockers, digoxin, or other nodal drugs on the MAR?
- Is there PR prolongation or AV block on the last ECG?
- For IV AF rate control: was WPW excluded and is cardioversion available?
- Did I teach constipation prevention and ask about grapefruit juice?
Verapamil NCLEX practice questions
Practice NCLEX-style clinical judgment practice for verapamil using a tabbed case (MAR, labs, vitals, nursing notes), then priority action, cue recognition, trend interpretation, ordered IV safety steps, WPW contraindication, and matrix urgency sorting—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Verapamil ER 240 mg PO daily — scheduled 0800; dose held yesterday for HR 52
- Metoprolol tartrate 25 mg PO BID — given 0800 today
- Digoxin 0.125 mg PO daily — given 0800 today
- Simvastatin 20 mg PO nightly — ordered
- PRN verapamil IV 5 mg slow push available if ordered for rapid AF rate control
- BMP today: sodium 139 mEq/L, potassium 4.3 mEq/L, creatinine 1.1 mg/dL, glucose 98 mg/dL
- Digoxin level 1.0 ng/mL (drawn 0700 — therapeutic range per facility protocol)
- Hepatic panel WNL on admission
- Magnesium 2.0 mg/dL
- Apical pulse 47/min regular — patient reports mild dizziness when walking
- BP 102/64 mmHg, SpO2 96% on room air
- Telemetry: sinus rhythm, PR 220 ms (baseline PR 180 ms yesterday)
- Weight 68 kg stable; last bowel movement 4 days ago
- 71-year-old admitted for hypertension and paroxysmal AF history; no documented WPW on chart
- 0730: Patient lightheaded transferring to bathroom after metoprolol and digoxin
- 0740: Nurse preparing to resume verapamil ER after yesterday’s hold when HR was 52
- 0745: Pharmacy flagged simvastatin 20 mg with verapamil ER 240 mg interaction
Answer key & rationale
Frequently asked questions
When should a nurse hold verapamil?
Hold verapamil and notify the prescriber or pharmacist for symptomatic bradycardia, second- or third-degree AV block without pacemaker, systolic blood pressure below 90 mmHg, syncope, or suspected overdose. Hold IV verapamil for AF or flutter when atrial fibrillation or flutter is associated with Wolff-Parkinson-White syndrome. Do not give IV verapamil within a few hours of IV beta-blocker per labeling.
Can verapamil be given with a beta-blocker?
Labeling notes combination therapy is often tolerated but data are insufficient to predict effects in left ventricular dysfunction or conduction disease. Additive AV conduction slowing can cause bradycardia or heart block. IV verapamil and IV beta-blockers must not be administered together or within a few hours. Monitor heart rate and blood pressure closely when oral agents overlap.
Why is IV verapamil contraindicated for AF with WPW?
Verapamil slows AV nodal conduction but does not prolong accessory pathway refractoriness. In atrial fibrillation or flutter with Wolff-Parkinson-White syndrome, this can shunt conduction through the bypass tract and cause a potentially life-threatening increase in ventricular rate with hypotension. Use only in monitored settings with defibrillation available when WPW is excluded.
Why is constipation common with verapamil?
Constipation occurred in 7.3% of patients in oral verapamil clinical trials. Teach fiber, fluids, activity, and bowel regimen per prescriber; report severe constipation because reversible paralytic ileus has been reported per labeling.
Is there an antidote for verapamil overdose?
No specific antidote exists. Overdose may cause bradycardia, hypotension, heart block, and heart failure. Supportive care includes IV calcium, beta-adrenergic stimulation, atropine, pacing, vasopressors, and inotropes per labeling. Hemodialysis is not beneficial. Observe at least 48 hours after oral overdose when sustained-release products are involved. Contact local poison control or medical toxicology services per facility protocol.
References
-
U.S. National Library of Medicine. Verapamil hydrochloride tablets, USP tablets — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ed1e0c14-3571-43f9-88fc-5a4d2b598263
-
U.S. National Library of Medicine. Verapamil hydrochloride injection — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1c993365-1b62-4524-e781-d307f28f63bc
-
U.S. National Library of Medicine. Verapamil hydrochloride extended-release capsules (PM) — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5f665d08-e1e4-422a-88c2-d8834abf9e1a
-
Drugs and Lactation Database (LactMed). Verapamil. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/n/lactmed/LM277/
-
U.S. National Library of Medicine. MedlinePlus: Verapamil. NIH patient drug information summary.https://medlineplus.gov/druginfo/meds/a684027.html
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.